To the Editor.—The editorial by Kissin1 rightly calls attention to the many difficulties facing the investigator who seeks to demonstrate the clinical phenomenon of preemptive anesthesia. To his balanced words, I add that I believe semantic confusion has arisen because of misuse of the word “preemptive.” Increasingly, this word is equated by those who conduct clinical trials or review the literature with “preoperative” or “pre-incision.” In the animal literature, however, the term “preemptive” refers to measures that prevent sensitization of cells within the spinal cord dorsal horn and other key sites within pain pathways. By definition, preemptive interventions in animal models must be accomplished before the onset of nociception. Conversely, preoperative or pre-incisional measures that could not possibly be viewed as preventing dorsal horn sensitization have been tested as if they were preemptive in the preceding sense. For example, the administration of single dose of a nonsteroidal antiinflammatory drug, or a single low dose of an opioid preoperatively, have been evaluated in clinical trials whose results are then discussed as tests of “preemptive analgesia.”

It is clear from the preclinical literature that preemptive means “preventive,” not simply “before.” Preemptive analgesia, like many other potentially worthwhile advances in medicine, would be abandoned if its initial, sometimes uncritical implementation were viewed as a final test of its value. Cardiopulmonary bypass, blood transfusion, organ transplantation, and the use of muscle relaxants are but a few examples. Kissin does well to caution his colleagues that even effects that do exist and that may be of extreme importance are not always evident. For these reasons, we should not allow linguistic impression to compound our difficulties when evaluating this important concept.

Daniel B. Carr, M.D., F.A.R.P.M.
Saltonstall Professor of Pain Research
Vice-Chairman for Research
Medical Director, Pain Management Program
Department of Anesthesiology
Professor of Anesthesiology and Medicine
Tufts University School of Medicine

Anesthesiology, V 85, No 6, Dec 1996
Treatment of Intracranial Hypertension with Indomethacin

To the Editor—Recently, Nilsson et al.1 concluded that intravenous infusion of indomethacin in doses of 0.3 and 3 mg/kg/h, but not 0.1 mg/kg/h, caused a constrictor effect in cerebral blood flow (CBF) accompanied by a progressive increase in cerebral arteriovenous oxygen difference, a decrease in jugular venous pH, and slowing of electroencephalographic activity, indicating cerebral ischemia. In addition, they found a progressive increase in intracranial pressure (ICP) during and after indomethacin infusion in two pigs, suggesting that the vasodilatation was so pronounced that ischemic lesions had developed. The authors did not find that their studies supported the clinical use of indomethacin in the treatment of intracranial hypertension due to head injury.

The authors analyzed our article,2 in which we studied the effects of indomethacin (30 mg intravenously, followed by 30 mg/h for 7 h) in five patients with severe head injury with resistant intracranial hypertension. All patients had focal cerebral contusion and edema, with compression of the ventricular system and basal cisterns. On average, we found an instantaneous decrease in ICP from 28 to 17 mmHg (mean value) accompanied by a decrease in CBF, an increase in the arteriovenous oxygen content difference (AVDO₂) at 2 h of indomethacin administration, and a decrease in arteriovenous lactate difference (at 15 min). At conclusion of the study, 1–6 months after head trauma, all patients had regained consciousness. We concluded that the effect of indomethacin on intracranial hypertension in patients with severe head injury was promising, but the cerebral vasodilator effect of indomethacin was potentially dangerous because it might provoke cerebral ischemia. However, subsequent follow-up of these patients revealed nothing that could obviously be linked to indomethacin use. Our preliminary result was confirmed recently in another clinical study.3 Since then, we compared the effect of indomethacin with that of acute hyperventilation in patients with severe head injury, and found that 30 mg indomethacin as a bolus injection caused a decrease in ICP comparable with a decrease in PaCO₂ of 0.88 kPa. In the same study, the degree of change in AVDO₂, jugular venous saturation, arteriovenous lactate difference, and lactate/oxygen index did not differ between hypocapnia and indomethacin.4 These studies were supplemented with other studies of healthy volunteers, in which hypoxia and hypocapnia restored the indomethacin-induced CBF decrease,5 and a dose–response study in which 0.1 mg/kg/h indomethacin reduced CBF significantly.6 In another clinical study, the effects of 30 mg indomethacin during cranio-